Navigation Links
Study Finds Pre-Hospital Administration Of Bivalirudin Substantially Improves Outcomes Compared To Heparin In Heart Attack Patients
Date:10/30/2013

SAN FRANCISCO, Oct. 30, 2013 /PRNewswire-USNewswire/ -- According to a new study, administering the blood thinner bivalirudin to patients experiencing an ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) in a pre-hospital setting can reduce the risk of death and major bleeding complications compared to heparin with optional use of glycoprotein IIb/IIIa inhibitors.

Findings from the EUROMAX trial were reported today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Results of the trial were simultaneously published today in the New England Journal of Medicine.

The EUROMAX trial evaluated the administration of anticoagulant therapy prior to hospital admission by an emergency medical team. The trial compared a heparin-based strategy (with or without glycoprotein IIb/IIIa receptor inhibitors (GPIs) to a bivalirudin-based strategy. The primary endpoint was a composite incidence of death or non-coronary-artery-bypass-graft related protocol major bleeding at 30 days, assessed by intention to treat.

While bivalirudin has been compared to other blood thinners in hospital settings, the EUROMAX study is the first to evaluate these anticoagulant therapy options prior to hospital admission and in conjunction with newer P2Y12 inhibitors such as prasugrel and ticagrelor. The randomized, international, prospective, open-label ambulance trial enrolled 2,198 patients with STEMI and intended for primary PCI, presenting either via ambulance or to centers where PCI is not performed.

Patients either received bivalirudin (n=1,089) or heparin (n=1,109) at guideline-recommended doses (with or without routine or bailout GPI).

After 30 days, patients that received bivaliru
'/>"/>

SOURCE Cardiovascular Research Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
2. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
3. Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
4. Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
5. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
6. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
7. New Study Shows Promise For First Effective Medicine To Treat Cocaine Dependence
8. Philips and RealView Imaging conclude worlds first study to evaluate live 3D holographic imaging in interventional cardiology
9. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
10. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)...   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue ... media and a related cloud hosted biologistics ... shippers ("BioLife" or the "Company"), today announced ... company focused on developing and commercializing novel therapeutics ...
(Date:8/28/2015)... JACKSONVILLE, Fla. , Aug. 28, 2015  With ... reaching deadlier heights, Jacksonville ... Philip Hemphill is helping to explain why ... Fentanyl is approximately 40 to 50 times more potent ... by recreational users as heroin, the risk of death ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... WASHINGTON, Sept. 8, 2011 ... in global bribery trends and risk mitigation strategies have ... them with today,s launch of the new TRACE website. ... site offers an array of valuable and practical resources ...
... 8, 2011 As the country,s economic recovery continues ... new research from the National Association of Chain ... drugstores have opened in the last two years while ... "This new drugstore research runs counter to ...
Cached Medicine Technology:TRACE Launches Enhanced Anti-Bribery Compliance Website 2
(Date:8/31/2015)... ... September 01, 2015 , ... The PT Outcomes Registry is an organized ... physical therapy patients. The Registry is being developed by the American Physical Therapy Association ... happy to be selected to contribute FOTO Outcomes measures as one of the primary ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global Translations website, ... for specific translation services within the medical and pharmaceutical industries. These are industries ... successful work. , ITC Global Translations specializes in professional translation services for materials ...
(Date:8/31/2015)... Florida (PRWEB) , ... August 31, 2015 , ... ... health insurance, announced today their new “ InstantQuote ” tool, which summarizes all ... and easy-to-understand format. The technology tool is designed to help India Network members ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... postnatal fitness classes. , Starting September 1st they are offering pre ... Mom Bod" and "Healthy Body, Healthy Baby." , More information can be found ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning documentary “Alive ... “Alive Inside” shadows a social worker who advocates for the use of music therapy ... bringing music to residents in health care centers who may have lost a spark ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2
... developed by scientists at The Wistar Institute in Philadelphia ... globe through the catalog collection at the Coriell Institute ... collaboration means that scientists at a variety of research ... use in the development of vaccines and treatments for ...
... Medical Simulation Corporation (MSC),will present a ... at the SCAI/ACC national conference in,Chicago, Illinois, ... place on,Monday, March 31 at 1:30 p.m. ... The presentation represents a milestone in simulation ...
... Calif., March 25 Evalve, Inc., the leader,in the ... announced today CE Mark approval for its MitraClip(R) system. ... a,non-surgical option for patients suffering from the effects of ... of heart valve insufficiency in the United,States and the ...
... and Others Among First to Carry New Package, ... of Dog,On It! fortified juice beverage for kids, announced ... product line to five all natural,fruit-filled beverages. Shaw,s, ShopRite ... On It!, will be among a host of leading,retailers ...
... John McCain understands how to address the,challenges facing ... WASHINGTON, March 25 John McCain claims he,delivers ... speech today in,Los Angeles, the Republican candidate will ... his previous health care proposals show that,he doesn,t. ...
... or shortsightedness reveals that people who wear glasses are ... busted the myth that people who wear glasses are ... more likely to be agreeable and open, rather than ... University of Melbournes Centre for Eye Research Australia. , ...
Cached Medicine News:Health News:The Wistar Institute collaborates with the Coriell Institute to distribute cell lines 2Health News:Medical Simulation Corporation to Present Comprehensive Cardiac Patient Scenario at the Society for Cardiovascular Angiography and Interventions (SCAI) and American College of Cardiology (ACC) Conference 2Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 2Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 3Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 4Health News:White Hat Brands Takes Dog On It! Fortified Juice Beverage for Kids to New Heights 2Health News:DNC McCain Myth Buster: John McCain and Health Care 2Health News:Mythbusted -- people who wear glasses aren't geeks 2
... The Sound Pro Combination ... table solution, combining the ... the Ultra Pro and ... ideal for OB/GYN, general ...
...
... primers and a FAM-labeled probe that is designed ... mecA gene. In addition, this ASR contains primers, ... internal control sequence. This ASR requires an instrument ... dyes such as the Cepheid SmartCycler System. The ...
... Device features the ability to use a ... and a pre-loaded nitinol filter with a ... a fully rapid exchange system, the SpideRX ... indicated applications:, Carotid Indication - ,The SpideRX ...
Medicine Products: